WNT and β-catenin signalling: Diseases and therapies

Nature Reviews Genetics

Volumn 5, Issue 9, 2004, Pages 691-701

  Moon, Randall T ^a   Kohn, Aimee D ^a   De Ferrari, Giancarlo V ^a   Kaykas, Ajamete ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; CASEIN KINASE I; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LYMPHOID ENHANCER FACTOR 1; T CELL FACTOR PROTEIN; WNT PROTEIN;

ALZHEIMER DISEASE; BONE MASS; CALCIUM SIGNALING; CANCER; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME DUPLICATION; COLON CANCER; DISEASE ACTIVITY; DROSOPHILA MELANOGASTER; EMBRYO DEVELOPMENT; FIBROMATOSIS; HERMAPHRODITISM; HUMAN; HYPODONTIA; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; LEUKEMIA; LUNG CANCER; LUNG FIBROSIS; METASTASIS; MUTATION; NONHUMAN; OSTEOARTHRITIS; PHOCOMELIA; PRIORITY JOURNAL; REGENERATION; REPORTER GENE; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE; VITREORETINOPATHY; XENOPUS LAEVIS;

ANIMALS; BETA CATENIN; CYTOSKELETAL PROTEINS; FORECASTING; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; WNT PROTEINS;

DROSOPHILA MELANOGASTER; MELANOGASTER; XENOPUS LAEVIS;

EID: 4344584730     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1427     Document Type: Review

References (114)

1. Wodarz, A. & Nusse, R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14, 59-88 (1998).
2. Huelsken, J. & Birchmeier, W. New aspects of Wnt signaling pathways in higher vertebrates. Curr. Opin. Genet. Dev. 11, 547-553 (2001).
3. Veeman, M. T., Axelrod, J. D. & Moon, R. T. A second canon. Functions and mechanisms of β-catenin-independent Wnt signaling. Dev. Cell 5, 367-377 (2003).
4. Tolwinski, N. S. & Wieschaus, E. Rethinking WNT signaling. Trends Genet. 20,177-181 (2004).
5. Nelson, W. J. & Nusse, R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 303, 1483-1487 (2004).
6. He, X., Semenov, M., Tamai, K. & Zeng, X. LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: arrows point the way. Development 131, 1663-1677 (2004).
7. Tan, C. et al. Inhibition of integrin linked kinase (ILK) suppresses β-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin represser, snail, in APC-/- human colon carcinoma cells. Oncogene 20, 133-140 (2001).
8. Levina, E., Oren, M. & Ben-Ze'ev, A. Downregulation of β-catenin by p53 involves changes in the rate of β-catenin phosphorylation and Axin dynamics. Oncogene 23, 4444-4453 (2004).
9. Doble, B. W. & Woodgett, J. R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186 (2003).
10. Moon, R. T., Bowerman, B., Boutros, M. & Perrimon, N. The promise and perils of Wnt signaling through β-catenin. Science 296, 1644-1646 (2002).
11. Westfall, T. A. et al. Wnt-5/pipetail functions in vertebrate axis formation as a negative regulator of Wnt/β-catenin activity. J. Cell Biol. 162, 889-898 (2003).
12. Topol, L. et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation. J. Cell Biol. 162, 899-908 (2003).
13. Niemann, S. et al. Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. Am. J. Hum. Genet. 74, 558-563 (2004).
14. Jordan, B. K., Shen, J. H., Olaso, R., Ingraham, H. A. & Vilain, E. Wnt4 overexpression disrupts normal testicular vasculature and inhibits testosterone synthesis by repressing steroidogenic factor 1/β-catenin synergy. Proc. Natl Acad. Sci. USA 100, 10866-10871 (2003).
15. Perantoni, A. O. Renal development: perspectives on a Wnt-dependent process. Semin. Cell Dev. Biol. 14, 201-208 (2003).
16. Terada, Y. et al. Expression and function of the developmental gene Wnt-4 during experimental acute renal failure in rats. J. Am. Soc. Nephrol. 14, 1223-1233 (2003).
17. Surendran, K. & Simon, T. C. CNP gene expression is activated by Wnt signaling and correlates with Wnt4 expression during renal injury. Am. J. Physiol. Renal Physiol. 284, F653-F562 (2003).
18. Rodova, M., Islam, M. R., Maser, R. L. & Calvet, J. P. The polycystic kidney disease-1 promoter is a target of the β-catenin/T-cell factor pathway. J. Biol. Chem. 277, 29577-29583 (2002).
19. Olson, D. J. & Gibo, D. M. Antisense wnt-5a mimics wnt-1-mediated C57MG mammary epithelial cell transformation. Exp. Cell Res. 241, 134-141 (1998).
20. Olson, D. J., Gibo, D. M., Saggers, G.. Debinski, W. & Kumar, R. Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a. Cell Growth Differ. 8, 417-423 (1997).
21. Liang, H. et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4, 349-360 (2003). Strong evidence that WNT/calcium signalling is a tumour-suppressor pathway.
22. Weeraratna, A. T. et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288 (2002). Solid evidence that WNT/calcium signalling is involved in metastasis.
23. Ouko, L., Ziegler, T. R., Gu, L. H., Eisenberg, L. M. & Yang, V. W. Wnt11 signaling promotes proliferation, transformation and migration of IEC6 intestinal epithelial cells. J. Biol. Chem. 279, 26707-26715 (2004).
24. Miyaoka, T., Seno, H. & Ishino, H. Increased expression of Wnt-1 in schizophrenic brains. Schizophr. Res. 38, 1-6 (1999).
25. Katsu, T. et al. The human frizzled-3 (FZD3) gene on chromosome 8p21, a receptor gene for Wnt ligands, is associated with the susceptibility to schizophrenia. Neurosci. Lett. 353, 53-56 (2003).
26. Kozlovsky, N., Belmaker, R. H. & Agam, G. GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur. Neuropsychopharmacol. 12, 13-25 (2002).
27. Lijam, N. et al. Social interaction and sensorimotor gating abnormalities in mice lacking Dv11. Cell 90, 895-905 (1997).
28. Loughlin, J. et al. Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc. Natl Acad. Sci. USA 101, 9757-9762 (2004).
29. Easwaran, V. et al. β-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 63, 3145-3153 (2003).
30. Robitaille, J. et al. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nature Genet. 32, 326-330 (2002).
31. Toomes, C. et al. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am. J. Hum. Genet. 74, 721-730 (2004).
32. Kondo, H., Hayashi, H., Oshima, K., Tahira, T. & Hayashi, K. Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity. Br. J. Ophthalmol. 87, 1291-1295 (2003).
33. Xu, Q. et al. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell 116, 883-895 (2004).
34. Kaykas, A. et al. Mutant Frizzled 4 associated with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization. Nature Cell Biol. 6, 52-58 (2004).
35. Harada, S. & Rodan, G. A. Control of osteoblast function and regulation of bone mass. Nature 423, 349-355 (2003).
36. Johnson, M. L. et al. Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am. J. Hum. Genet. 60, 1326-1332 (1997).
37. Little, R. D. et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70, 11-19 (2002).
38. Boyden, L. M. et al. High bone density due to a mutation in LDL-receptor-relaled protein 5. N. Engl. J. Med. 346, 1513-1521(2002).
39. Zhang, Y. et al. The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol. Cell Biol. 24, 4677-4684 (2004).
40. Gong, Y. et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513-523 (2001). Evidence of LRPS involvement in bone and eye formation.
41. Bodine, P. V. et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol. Endocrinol. 18, 1222-1237 (2004).
42. Kahler, R. A. & Westendorf, J. J. Lymphoid enhancer factor-1 and β-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J. Biol. Chem. 278, 11937-11944 (2003).
43. Morin, P. J. & Weeraratna, A. T. Wnt signaling in human cancer. Cancer Treat Res. 115, 169-187 (2003).
44. Taketo, M. M. Shutting down Wnt signal-activated cancer. Nature Genet 36, 320-322 (2004).
45. Giles, R. H., van Es, J. H. & Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653, 1-24 (2003).
46. van de Wetering, M. et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111, 241-250 (2002).
47. Uematsu, K. et al. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 22, 7218-7221 (2003).
48. Kim, J. S., Crooks, H., Foxworth, A. & Waldman, T. Proof-of-principle: oncogenic β-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol. Cancer Ther. 1, 1355-1359 (2002).
49. Gunther, E. J. et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 17, 488-501 (2003).
50. Derksen, P. W. et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc. Natl Acad. Sci. USA 101, 6122-6127 (2004).
51. Suzuki, H. et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature Genet. 36, 417-422 (2004).
52. -/- mice. Genes Dev. 16, 3173-3185(2002).
53. Lammi, L. et al. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am. J. Hum. Genet 74, 1043-1050 (2004).
54. Mak, B. C., Takemaru, K., Kenerson, H. L., Moon, R. T. & Yeung, R. S. The tuberin-hamartin complex negatively regulates β-catenin signaling activity. J. Biol. Chem. 278, 5947-5951 (2003).
55. Fuchs, E., Tumbar, T. & Guasch, G. Socializing with the neighbors: stem cells and their niche. Cell 116, 769-778 (2004).
56. Chang, C. H. et al. Distinct Wnt members regulate the hierarchical morphogenesis of skin regions (spinal tract) and individual feathers. Mech. Dev. 121, 157-171 (2004).
57. Zhu, A. J. & Watt, F. M. β-catenin signalling modulates proliferative potential of human epidermal keratinocytes independently of intercellular adhesion. Development 126, 2285-2298 (1999).
58. Chan, E. F., Gat, U., McNiff, J. M. & Fuchs, E. A common human skin tumour is caused by activating mutations in β-catenin. Nature Genet 21, 410-413 (1999).
59. Quo, N., Hawkins, C. & Nathans, J. From the cover: Frizzled6 controls hair patterning in mice. Proc. Natl Acad. Sci. USA 101, 9277-9281 (2004).
60. Cheon, S. S. et al. β-catenin Stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc. Natl Acad. Sci. USA 99, 6973-6978 (2002).
61. Cheon, S. S., Nadesan, R, Poon, R. & Alman, B. A. Growth factors regulate β-catenin-mediated TCP-dependent transcriptional actuation in fibroblasts during the proliferative phase of wound healing. Exp. Cell Res. 293, 267-274 (2004).
62. Varallo, V. M. et al. β-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating β-catenin levels in vivo and in vitro. Oncogene 22, 3680-3684 (2003).
63. Morrisey, E. E. Wnt signaling and pulmonary fibrosis. Am. J. Pathol. 162, 1393-1397 (2003).
64. Mucenski, M. L. et al. β-catenin is required for specification of proximal/distal cell fate during lung morphogenesis. J. Biol. Chem. 278, 40231-40238 (2003).
65. Chilosi, M. et al. Aberrant Wnt/β-catenin pathway activation in idiopathic pulmonary fibrosis. Am. J. Pathol. 162, 1495-1502 (2003).
66. Okubo, T. & Hogan, B. L. Hyperactive Wnt signaling changes the developmental potential of embryonic lung endoderm. J. Biol. 3, 11 (2004).
67. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
68. Terry, A. V. & Buccafusco, J. J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 306, 821-827 (2003).
69. Zhang, Z. et al. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395, 698-702 (1998).
70. Nishimura, M. et al. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of β-catenin, a component of the presenilin protein complex. Nature Med. 5, 164-169 (1999).
71. Takashima, A. et al. Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau. Proc. Natl Acad. Sci. USA 95, 9637-9641 (1998).
72. De Ferrari, G. V. & Inestrosa, N. C. Wnt signaling function in Alzheimer's disease. Brain Res. Brain Res. Rev. 33, 1-12 (2000).
73. Kang, D. E. et al. Presenilin couples the paired phosphorylation of β-catenin independent of axin: implications for β-catenin activation in tumorigenesis. Cell 110, 751-762 (2002).
74. Mudher, A. & Lovestone, S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci. 25, 22-26 (2002).
75. Caricasole, A. et al. The Wnt pathway, cell-cycle activation and β-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol. Sci. 24, 233-238 (2003).
76. Mudher, A. et al. Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. J. Neurosci. 21, 4987-4995 (2001).
77. Alvarez, G. et al. Lithium protects cultured neurons against β-amytoid-induced neurodegeneration. FEBS Lett. 453, 260-264 (1999).
78. De Ferrari, G. V. et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils. Mol. Psychiatry 8, 195-208 (2003). Evidence that activating WNT/β-catenin signalling is neuroprotective in vitro and in vivo.
79. Phiel, C. J., Wilson, C. A., Lee, V. M. & Nein, P. S. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435-439 (2003).
80. Sun, X. et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. 321, 61-64 (2002).
81. Olson, E. N. & Schneider, M. D. Sizing up the heart: development redux in disease. Genes Dev. 17, 1937-1956 (2003).
82. Nakamura, T., Sano, M., Songyang, Z. & Schneider, M. D. A Wnt- and β-catenin-dependent pathway for mammalian cardiac myogenesis. Proc. Natl Acad. Sci. USA 100, 5834-5839 (2003).
83. Pandur, P., Lasche, M., Eisenberg, L. M. & Kuhl, M. Wnt-11 activation of a non-canonical Wnt signalling pathway is required for cardiogenesis. Nature 418, 636-641 (2002).
84. van Gijn, M. E., Daemen, M. J., Smits, J. F. & Blankesteijn, W. M. The wnt-frizzled cascade in cardiovascular disease. Cardiovasc. Res. 55, 16-24 (2002).
85. Barandon, L. et al. Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation 108, 2282-2289 (2003).
86. Lepourcelet, M. et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 5, 91-102 (2004).
87. Emami, K. H. et al. A small molecule inhibitor of β-catenin/CBP transcription. Proc. Natl Acad. Sci. USA (in the press). New lead anti-cancer compound that blocks the WNT/β-catenin pathway.
88. He, B. et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6, 7-14 (2004).
89. You, L. et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 21 June 2004 [epub ahead of print].
90. Chakrabarty, S., Radjendirane, V., Appelman, H. & Varani, J. Extracellular calcium and calcium sensing receptor function in human colon carcinomas: promotion of E-cadherin expression and suppression of β-catenin/TCF activation. Cancer Res. 63, 67-71 (2003).
91. Boon, E. M. et al. Sulindac targets nuclear (5-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br. J. Cancer 90, 224-229 (2004).
92. Dihlmann, S., Klein, S. & Doeberitz, M. K. Reduction of β-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated β-catenin. Mol. Cancer Ther. 2, 509-516 (2003).
93. Nath, N., Kashfi, K., Chen, J. & Rigas, B. Nitric oxide-donating aspirin inhibits β-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear β-catenin-TCF association. Proc. Natl Acad. Sci. USA 100, 12584-12589 (2003).
94. Lu, D. et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 101, 3118-3123 (2004).
95. Thompson, W. J. et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res. 60, 3338-3342 (2000).
96. Zhou, L. et al. Tyrosine kinase inhibitor STI-571/Gleevec downregulates the β-catenin signaling activity. Cancer Lett. 193, 161-170 (2003).
97. Suksaweang, S. et al. Morphogenesis of chicken liver, identification of localized growth zones and the role of β-catenin/Wnt in size regulation. Dev. Biol. 266, 109-122 (2004).
98. Chenn, A. & Walsh, C. A. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 297, 365-369 (2002).
99. Ross, S. E. et al. Inhibition of adipogenesis by Wnt signaling. Science 289, 950-953 (2000).
100. Kielman, M. F. et al. Ape modulates embryonic stem-cell differentiation by controlling the dosage of β-catenin signaling. Nature Genet. 32, 594-605 (2002).
101. Kubo, F., Takeichi, M. & Nakagawa, S. Wnt2b controls retinal cell differentiation at the ciliary marginal zone. Development 130, 587-598 (2003).
102. Sato, N., Meijer, L, Skaitsounis, L., Greengard, P. & Brivanlou, A. H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nature Med. 10, 55-63 (2004).
103. Eaves, C. J. Manipulating hematopoietic stem cell amplification with Wnt. Nature Immunol. 4, 511-512 (2003).
104. Lee, H. Y. et al. Instructive role of Wnt/β-catenin in sensory fate specification in neural crest stem cells. Science 303, 1020-1023 (2004).
105. Liu, B. Y., McDermott, S. P., Khwaja, S. S. & Alexander, C. M. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl Acad. Sci. USA 101, 4158-4163 (2004).
106. + adult stem cells during muscle regeneration. Cell 113, 841-852 (2003).
107. Reya, T. et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423, 409-414 (2003).
108. Wiltert, K. et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423, 448-452 (2003). Purification of WNTs and demonstration of their potential effects on stem cells.
109. Murdoch, B. et al. Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo. Proc. Natl Acad. Sci. USA 100, 3422-3427 (2003).
110. Castelo-Branco, G. et al. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc. Natl Acad. Sci. USA 100, 12747-12752 (2003).
111. Korinek, V. et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nature Genet. 19, 379-383 (1998).
112. Kuhnert, F. et al. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc. Natl Acad. Sci. USA 101, 266-271 (2004).
113. Kim, J. H. et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinsons disease. Nature 418, 60-56 (2002).
114. Hori, Y. et al. Growth inhibitors promote differentiation of insulin-producing tissue from embryonic stem cells. Proc. Natl Acad. Sci. USA 99, 16105-16110 (2002).